NOVOS Core trial reports vascular gains in healthy adults

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Six-month University of Surrey RCT sees better endothelial function, less arterial stiffness and lower systolic pressure – but lipids unmoved.

Supplements tend to make promises; arteries tend to keep score. In a randomized, double-blind, placebo-controlled trial published in the European Heart Journal Open, six months of daily NOVOS Core improved endothelial function, eased arterial stiffness and trimmed systolic blood pressure in apparently healthy adults over 40 – a cohort whose vascular measures already sat within normal ranges, leaving little slack to take up [1].

Professor Christian Heiss and his University of Surrey team took a question geroscience has been worrying at for years and gave it a cuff, an ultrasound probe and six months. If aging runs on interlocking mechanisms, should a formulation that prods several at once leave a mark on the plumbing downstream? Stiffening and faltering long before anyone notices, arteries make honest witnesses.

Longevity.Technology: There is a great deal to like here. A company putting its flagship formulation through a blinded, university-run RCT and then submitting it to a cardiology journal is doing what most of the supplement aisle does not; that the primary endpoint was flow-mediated dilation, measured by a group that published the FMD reference values, adds considerable weight. The effect sizes are not trivial, either. A little calibration is still in order, though. Forty-three completers make a small sample, the control arm was older at randomization (a gap the authors acknowledge) and compliance rested on dosing diaries. The six-month readings were taken roughly 24 hours after the last dose rather than after a washout, so whether this is lasting vascular adaptation or the residual glow of yesterday’s scoop remains open; with 12 ingredients in the tub, the paper is candid that it “cannot identify the active ingredient(s)”. One small point of translation, too – the release describes carotid-femoral PWV, while the paper measured it with a cuff-based oscillometric device, a reasonable proxy but not quite the gold standard. None of this diminishes the result; it simply sketches the brief for the next trial. The interesting question now is whether the arteries keep listening.

The trial randomized 61 non-smokers aged 40 and over: 33 to NOVOS Core, 28 to a placebo matched for look and taste. Women made up 31 of them. The daily 15-gram scoop held a dozen ingredients – vitamin C, magnesium malate, calcium alpha-ketoglutarate, glycine, glucosamine sulphate, Rhodiola rosea, L-theanine, hyaluronic acid, fisetin, ginger root extract, pterostilbene and lithium aspartate – which is a good deal of chemistry for one glass of water [1].

The primary endpoint delivered. FMD rose by 2.6% from baseline in the supplement group while barely shifting in controls, an adjusted between-group difference of 2.9 percentage points – roughly a 47% relative improvement on baseline. Pulse wave velocity fell by 0.78 m/s with NOVOS Core and rose by 0.56 m/s on placebo, an adjusted difference of 1.18 m/s; systolic pressure dropped 6.1 mmHg more than in controls. Lipids stayed put, so the modest fall in estimated 10-year cardiovascular risk (SCORE2/SCORE2-OP) was, as the authors put it, “primarily attributable to lower systolic blood pressure rather than lipid change”. Notably, FMD was already 3.9 percentage points above placebo an hour after the first serving [1].

“I founded NOVOS to answer one question: what can a person do to slow the aging process and stay healthier for longer?” said Chris Mirabile, Founder and CEO of NOVOS.

Chris Mirabile is the Founder and CEO of NOVOS

“A credible answer demands the scrutiny medicine applies to anything it takes seriously, which means a blinded, placebo-controlled trial run by university researchers and reviewed by their peers. People deserve that level of proof from every company that puts the word ‘longevity’ on a label, and we intend to keep meeting it.”

Heiss was characteristically measured. “Our hypothesis in this study was whether a multi-component supplement addresses many biological and biochemical processes related to vascular aging and has an effect on measures of vascular health. We found favourable changes in endothelial function, arterial stiffness and systolic blood pressure after six months,” he said. “These findings are encouraging, and supplements can be a part of a healthy lifestyle.”

For Diogo Barardo, PhD, NOVOS’ Director of R&D and a coauthor on the paper, the vasculature was the obvious proving ground. “The cardiovascular system supplies every cell and organ in the body, it is one of the first systems to show signs of aging, and cardiovascular disease is the leading cause of death for men and women in the United States and worldwide,” he said. “That made it the natural place to test our hypothesis that targeting the hallmarks of aging would improve cardiovascular health. The STAMINA results indicate it did, and in healthy adults, whose measures already sit close to normal and are among the hardest to move.”

The trial was Surrey’s idea; the formulation, the placebo and an unrestricted research contribution came from NOVOS. The paper is clear that the company played no part in the design, the primary analysis or the decision to publish.

Why do a few millimeters of mercury matter? The authors point to meta-analyses in which each 1% gain in FMD tracks with roughly 10% lower cardiovascular risk, and to a participant-level analysis of more than 344,000 people in which a 5 mmHg fall in systolic pressure went with about 10% fewer major cardiovascular events. Surrogates are IOUs, though. Their value depends on whether the effect lasts and whether larger, more varied cohorts can repeat it.

NOVOS says it is now weighing follow-up studies in muscle, cognition and skin, alongside work on biological aging itself. The more revealing experiment may be the less glamorous one – the component-deconstruction design the paper itself calls for. A multi-target formula is a reasonable answer to a multi-causal process; knowing which targets are doing the work would turn a promising result into a usable map.


Wondering which longevity companies are putting their products through human trials? Ask DLT to “show me longevity companies with peer-reviewed clinical trials of nutraceutical interventions” or to “identify companies developing interventions that target vascular aging” – explore the platform HERE.

Photographs courtesy of NOVOS

[1] https://academic.oup.com/ehjopen/article/6/6/oeag157/8840868

Eleanor Garth

Editor

Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

With a keen interest in all things geroscience, Eleanor covers the biological mechanisms of aging, highlighting how interventions – from nutritional strategies to advanced therapeutics – can influence the aging process at a cellular level. She also investigates the broader implications of aging research, including the integration of longevity science into healthcare strategy and the expanding wellness economy. Her work (hopefully) provides insights into how these developments are shaping the emerging landscape of healthspan optimization and age-related innovation.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE